Herrero Torres Maria Angeles, Dominguez Bastante Mireia, Molina Raya Andrea, Palomo Lopez Irina, Santoyo Villalba Julio, Villegas Herrera Maria Trinidad, Becerra Massare Antonio, Brea Gomez Esther, Zambudio Carroll Natalia, Villar Del Moral Jesus Maria
Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Transplant Proc. 2020 Mar;52(2):592-593. doi: 10.1016/j.transproceed.2019.12.030. Epub 2020 Feb 10.
Cholangiocarcinoma is the second most common neoplasm in the liver, with a very poor, short-term prognosis. Today, surgery associated with or without an adjuvant is the only curative treatment. Liver transplantation (LT) is the best treatment for hepatocellular carcinoma tumor. In recent years, treatment of hilar cholangiocarcinoma by LT associated with neoadjuvant therapy has been studied under a criterion. But could it be possible to apply LT like the curative treatment of intrahepatic cholangiocarcinoma (iCC)? Initially the answer is no, but there are different studies about incidental LT in patients with iCC that demonstrate survival over 40% to 50%. In our center, we conducted a review of 468 transplants completed between 2002 and 2018, and we identified 1 case of incidental LT in a patient with iCC with an overall survival of 10 years. Because there is currently an increase in donors owing to the expansion of the criteria, a study to consider extending the criteria of LT to include iCC would be beneficial.
胆管癌是肝脏中第二常见的肿瘤，短期预后非常差。如今，无论有无辅助治疗的手术是唯一的治愈性治疗方法。肝移植（LT）是肝细胞癌肿瘤的最佳治疗方法。近年来，在一项标准下对新辅助治疗联合肝移植治疗肝门部胆管癌进行了研究。但是，能否像治疗肝内胆管癌（iCC）那样将肝移植作为治愈性治疗方法呢？最初的答案是否定的，但有不同的关于iCC患者意外肝移植的研究表明生存率超过40%至50%。在我们中心，我们对2002年至2018年完成的468例移植进行了回顾，我们确定了1例iCC患者意外肝移植且总生存期为10年的病例。由于目前由于标准的扩大供体有所增加，考虑将肝移植标准扩大到包括iCC的研究将是有益的。
